FDA Approval of the Pfizer-BioNTech COVID-19 Vaccine: Frequently Asked Questions

Bibliographic Details
Main Author:	Congressional Research Service
Format:	text
Published:	Congressional Research Service 2021
Online Access:	https://www.everycrsreport.com/reports/R46913.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Job aid for COVID-19 vaccine administration: COMIRNATY® Pfizer/BioNTech BNT162b2 vaccine, October 2021
by: World Health Organization. Regional Office for Europe
Published: (2021)

Job aid for COVID-19 vaccine administration: paediatric formulation of Pfizer–BioNTech COVID-19 vaccine, BNT162b2: February 2022
by: World Health Organization. Regional Office for Europe
Published: (2022)

Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing, 14 January 2021
by: World Health Organization
Published: (2021)

Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19 vaccine rollout, 1 February 2022
by: World Health Organization, et al.
Published: (2022)

Factsheet for health workers. Job aid for COVID-19 vaccine administration: paediatric formulation of Pfizer–BioNTech COVID-19 vaccine, BNT162b2: February 2022
by: World Health Organization. Regional Office for Europe
Published: (2022)

Job aid for COVID-19 vaccine administration: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (international nonproprietary name: tozinameran), February 2021
by: World Health Organization. Regional Office for Europe
Published: (2021)

Job aid for COVID-19 vaccine administration: Pfizer–BioNTech COVID-19 vaccine, BNT162b2: updated version: 7/07/2021 (International nonproprietary name: tozinameran)
by: World Health Organization. Regional Office for Europe
Published: (2021)

Памятка по применению вакцины против COVID-19: вакцина против COVID-19 компаний Pfizer–BioNTech, BNT162b2, Октябрь 2021 г.
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021
by: World Health Organization
Published: (2021)

Fact sheet for health workers: Pfizer–BioNTech COVID-19 vaccine, BNT162b2: updated version: 07/07/2021 (International nonproprietary name: tozinameran)
by: World Health Organization. Regional Office for Europe
Published: (2021)

Fact sheet for health workers: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (international nonproprietary name: tozinameran), February 2021
by: World Health Organization. Regional Office for Europe
Published: (2021)

mRNA vaccines against COVID-19: Pfizer-BioNTech COVID-19 vaccine BNT162b2: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines, 22 December 2020
by: World Health Organization
Published: (2020)

Памятка по применению вакцины против COVID-19: вакцина BNT162b2 Comirnaty® компаний Pfizer/BioNTech (международное непатентованное наименование: тозинамеран), Февраль 2021 r.
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

COVID-19 Testing: Frequently Asked Questions
by: Congressional Research Service
Published: (2021)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, first issued 8 January 2021, updated 15 June 2021
by: World Health Organization
Published: (2021)

Памятка по применению вакцины против COVID-19: вакцина против COVID-19 компаний Pfizer–BioNTech, BNT162b2. Обновленная версия от 07/07/2021 (международное непатентованное наименование: тозинамеран)
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

Информационный бюллетень для работников здравоохранения: вакцина BNT162b2 Comirnaty® компаний Pfizer/BioNTech (международное непатентованное наименование: тозинамеран), Февраль 2021 r.
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

Информационный бюллетень для работников здравоохранения: вакцина против COVID-19 компаний Pfizer–BioNTech, BNT162b2. Обновленная версия от 07/07/2021 (международное непатентованное наименование: тозинамеран)
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, first issued 8 January 2021, updated 15 June 2021, updated 19 November 2021
by: World Health Organization
Published: (2021)

Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19: grading of evidence - evidence to recommendation tables, first issued 14 January 2021 (included in the background document), updated 15 June 2021
by: World Health Organization
Published: (2021)

Frequently Asked Questions
by: Naval Postgraduate School (U.S.)
Published: (2013)

Antitrust Enforcement During the COVID-19 Pandemic: Frequently Asked Questions
by: Congressional Research Service
Published: (2020)

COVID-19 and Private Health Insurance Coverage: Frequently Asked Questions
by: Congressional Research Service
Published: (2021)

Medicare Accelerated and Advance Payments and COVID-19: Frequently Asked Questions
by: Congressional Research Service
Published: (2021)

Временные рекомендации по использованию вакцины BNT162b2, COVID-19, Pfizer - BioNTech, в соответствии с перечнем препаратов для применения в чрезвычайных ситуациях: временное руководство (8 января 2021 г.)
by: Всемирная организация здравоохранения. Европейское региональное бюро
Published: (2021)

Development and Regulation of Medical Countermeasures for COVID-19 (Vaccines, Diagnostics, and Treatments): Frequently Asked Questions
by: Congressional Research Service
Published: (2020)

Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 Pfizer-BioNTech, BNT162b2, en vertu du protocole OMS d’autorisation d’utilisation d’urgence : orientations provisoires, 8 janvier 2021
by: Organisation mondiale de la Santé
Published: (2021)

Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19: grading of evidence - evidence to recommendation tables, first issued 14 January 2021 (included in the background document), updated 15 June 2021, updated 19 November 2021
by: World Health Organization
Published: (2021)

Encryption: Frequently Asked Questions
by: Congressional Research Service
Published: (2016)

Firearms: Frequently Asked Questions
by: Congressional Research Service
Published: (2025)

LIBOR: Frequently Asked Questions
by: Congressional Research Service
Published: (2012)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, first issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022
by: World Health Organization
Published: (2022)

The U.S. Government’s Role in Domestic and Global COVID-19 Vaccine Supply and Distribution: Frequently Asked Questions
by: Congressional Research Service
Published: (2022)

Early Development and Regulation of Diagnostic Testing for COVID-19: Frequently Asked Questions
by: Congressional Research Service
Published: (2021)

Guía operativa sobre el establecimiento de un sistema de cadena de ultrafrío en apoyo del lanzamiento de la vacuna contra la COVID-19 de Pfizer-BioNTech, 1 de febrero de 2022
by: Organización Mundial de la Salud, et al.
Published: (2022)

Frequently asked questions in IFRS
by: Collings, Steve
Published: (2013)

Directives opérationnelles relatives à la mise en place d’un système de chaîne de froid à ultra-basse température pour soutenir le déploiement du vaccin Pfizer-BioNTech contre la COVID-19, 1er février 2022
by: Organisation mondiale de la Santé, et al.
Published: (2022)

The Internet of Things: Frequently Asked Questions
by: Congressional Research Service
Published: (2015)

Solar Energy: Frequently Asked Questions
by: Congressional Research Service
Published: (2023)

The 2020 Census: Frequently Asked Questions
by: Congressional Research Service
Published: (2020)

FDA Approval of the Pfizer-BioNTech COVID-19 Vaccine: Frequently Asked Questions

Similar Items

Similar Items